Esperion Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

Esperion Therapeutics

01/08/2025 15:30

Esperion Therapeutics Inc ESPR.OQ ESPR.O is expected to  show a fall in quarterly revenue when it reports  results on August 5 for the period ending June 30 2025

The Ann Arbor Michigan-based  company is expected to report a 13.6% decrease in revenue to $63.77 million from $73.83 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Esperion Therapeutics Inc is for a loss of 13 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Esperion Therapeutics Inc is $4.00, about 64.5% above its last closing price of $1.42

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.15
-0.15
-0.21
Missed
-35.6
Dec. 31 2025
-0.16
-0.15
-0.11
Beat
26.1
Sep. 30 2024
-0.18
-0.18
-0.15
Beat
14.6​
Jun. 30 2024
-0.17
-0.18
-0.33
Missed
-79.2
​​Mar. 31 2024
0.08
0.05
0.34
Beat
627.3
Dec. 31 2023
-0.41
-0.48
-0.50
Missed
-3.6​
Sep. 30 2023
-0.43
-0.43
-0.37
Beat
14.4
Jun. 30 2023
-0.62
-0.61
-0.46
Beat
24.8

This summary was machine generated August 1 at 14:30 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)